TLSC702
Based on 1 Customer Validation
TLSC702 is a human glyoxalase I (hGLO I) inhibitor with an IC50 of 2.0 μM. TLSC702 inhibits the activity of human glyoxalase I, thereby leading to the accumulation of methylglyoxal and its derived advanced glycation end products. TLSC702 inhibits tumor cell proliferation, induces apoptotic morphological changes, internucleosomal DNA fragmentation and PARP cleavage in tumor cells. TLSC702 can be used in research related to leukemia and lung cancer.
For research use only. We do not sell to patients.
- Purity: 95.61%
- CAS No.: 748786-57-4
- Formula: C18H15NO3S
- Molecular Weight:325.38
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
All DNA/RNA Synthesis Isoforms
More
Biological Activity
TLSC702 (24 h) suppresses the proliferation of human myeloid leukemia HL-60 cells in a dose-dependent manner with an EC50 of approximately 400 μM[1].
TLSC702 (100-1000 μM; 24 h) induces apoptosis in human myeloid leukemia HL-60 cells in a dose-dependent manner, as evidenced by morphological changes, DNA ladder formation, and PARP cleavage, with necrotic cell death also occurring at 1000 μM[1].
TLSC702 (24 h (both cell lines); 24, 48, 72 h (NCI-H522 cells only)) preferentially suppresses the proliferation of GLO I-high human lung cancer NCI-H522 cells compared to GLO I-low human lung cancer NCI-H460 cells, with a time-dependent antiproliferative effect on NCI-H522 cells that yields EC50 values of >300 μM (24 h), 202 μM (48 h), and 145 μM (72 h)[1].
TLSC702 (300 μM; 24, 48, 72 h) induces accumulation of argpyrimidine adducts in human lung cancer NCI-H522 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human myeloid leukemia HL-60 cells
-
Concentration:100, 300 and 1000 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent apoptotic morphological changes, including apoptotic bodies at 300 and 1000 μM.
Induced characteristic apoptotic DNA ladder formation in a dose-dependent manner at 300 μM.
Detected dose-dependent cleavage of PARP across tested concentrations.
Detected necrotic cell death at 1000 μM.
-
Cell Line:human lung cancer NCI-H522 cells
-
Concentration:300 μM
-
Incubation Time:24, 48, 72 h
-
Result:Induced accumulation of argpyrimidine adducts (methylglyoxal-derived advanced glycation end-products) in NCI-H522 cells.
Chemical Information
-
CAS No. 748786-57-4
-
Appearance Solid
-
Molecular Weight 325.38
-
Formula C18H15NO3S
-
Color Light yellow to yellow
-
SMILES
O=C(O)CC(=CC1=CC=C(OC)C=C1)C2=NC=3C=CC=CC3S2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (153.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.84 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.84 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0733 mL | 15.3666 mL | 30.7333 mL | 76.8332 mL |
| 5 mM | 0.6147 mL | 3.0733 mL | 6.1467 mL | 15.3666 mL | |
| 10 mM | 0.3073 mL | 1.5367 mL | 3.0733 mL | 7.6833 mL | |
| 15 mM | 0.2049 mL | 1.0244 mL | 2.0489 mL | 5.1222 mL | |
| 20 mM | 0.1537 mL | 0.7683 mL | 1.5367 mL | 3.8417 mL | |
| 25 mM | 0.1229 mL | 0.6147 mL | 1.2293 mL | 3.0733 mL | |
| 30 mM | 0.1024 mL | 0.5122 mL | 1.0244 mL | 2.5611 mL | |
| 40 mM | 0.0768 mL | 0.3842 mL | 0.7683 mL | 1.9208 mL | |
| 50 mM | 0.0615 mL | 0.3073 mL | 0.6147 mL | 1.5367 mL | |
| 60 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.2806 mL | |
| 80 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.9604 mL | |
| 100 mM | 0.0307 mL | 0.1537 mL | 0.3073 mL | 0.7683 mL |
TLSC702 Related Classifications
HY-117208 Related Classifications
Powered by Bioz
- TLSC702
- 748786-57-4
- TLSC 702
- TLSC-702
- Glyoxalase (GLO)
- Apoptosis
- DNA/RNA Synthesis
- PARP
- human myeloid leukemia HL-60 cells
- leukemia
- human lung cancer NCI-H522 cells
- methylglyoxal
- apoptosis
- advanced glycation end-products
- lung cancer
- human glyoxalase I
- PARP cleavage
- human lung cancer NCI-H460 cells
- Inhibitor
- inhibitor
- inhibit